France
ALSYMO
Against pulmonary arterial hypertension, ALSYMO develops a first-in-class drug candidate: it is a patented peripheral NMDA receptor antagonist able to inhibit the thickening of blood vessels, at the origin of the increase in blood pressure in the lungs.
